Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics

Current Drug Metabolism

Volumn 14, Issue 2, 2013, Pages 226-238

  Huang, Zeqi ^a   Ung, Thao ^b  

^a CEPHALON INC   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

AGP; Alpha 1 acid glycoprotein; Drug binding protein; PD; PK; Plasma binding; Species difference

Indexed keywords

ACENOCOUMAROL; AMITRIPTYLINE; AMLODIPINE; BINEDALINE; CHLORPROMAZINE; DERAMCICLANE; DIPYRIDAMOLE; DISOPYRAMIDE; FLUOXETINE; GIMATECAN; HALOPERIDOL; IMATINIB; IMIPRAMINE; LERISETRON; LIDOCAINE; METHADONE; MIFEPRISTONE; NORTRIPTYLINE; OROSOMUCOID; OXYBUTYNIN; PENBUTOLOL; PHENPROCOUMON; PINDOLOL; PROPAFENONE; PROPRANOLOL; ROPIVACAINE; TAMSULOSIN; UNINDEXED DRUG; VISMODEGIB; WARFARIN;

AGE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BURN; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIONS ASSOCIATED WITH OTHER INFECTIONS OR CONDITIONS; INFLAMMATORY DISEASE; INJURY; NEOPLASM; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOLID TUMOR; SURGERY;

EID: 84877964858     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314020011     Document Type: Article

References (144)

1. Israili, Z.H.; Dayton, P.G. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev., 2001, 33, 161-235. (Pubitemid 32703255)
2. Kremer, J.M.; Wilting, J.; Janssen, L.H. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev., 1988, 40, 1-47.
3. El-Gamel, S.; Wollert, U.; Muller, W.E. Optical studies on the specific interaction of dipyridamole with alpha 1-acid glycoprotein (orosomucoid). J. Pharm. Pharmacol., 1982, 34, 152-157. (Pubitemid 12114326)
4. Steele, W.H.; Haughton, D.J.; Barber, H.E. Binding of vinblastine to recrystallized human alpha 1-acid glycoprotein. Cancer Chemother. Pharmacol., 1982, 10, 40-42. (Pubitemid 13167314)
5. Schley, J.; Muller-Oerlinghausen, B. The binding of chemically different psychotropic drugs to alpha 1-acid glycoprotein. Pharmacopsychiatria., 1983, 16, 82-85. (Pubitemid 13066975)
6. Walle, U.K.; Walle, T.; Bai, S.A.; Olanoff, L.S. Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin. Pharmacol. Ther., 1983, 34, 718-723. (Pubitemid 14219916)
7. Fuse, E.; Tanii, H.; Takai, K.; Asanome, K.; Kurata, N.; Kobayashi, H.; Kuwabara, T.; Kobayashi, S.; Sugiyama, Y. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res., 1999, 59, 1054-1060. (Pubitemid 29135966)
8. Fitos, I.; Visy, J.; Zsila, F.; Mady, G.; Simonyi, M. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. Biochim. Biophys. Acta, 2006, 1760, 1704-1712. (Pubitemid 44667264)
9. Boffito, M.; Back, D.J.; Blaschke, T.F.; Rowland, M.; Bertz, R.J.; Gerber, J.G.; Miller, V. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses, 2003, 19, 825-835. (Pubitemid 37215138)
10. Colombo, S.; Buclin, T.; Decosterd, L.A.; Telenti, A.; Furrer, H.; Lee, B.L.; Biollaz, J.; Eap, C.B. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin. Pharmacol. Ther., 2006, 80, 307-318. (Pubitemid 44479747)
11. Zsila, F.; Fitos, I.; Bencze, G.; Keri, G.; Orfi, L. Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr. Med. Chem., 2009, 16, 1964-1977.
12. Graham, R.A.; Lum, B.L.; Cheeti, S.; Jin, J.Y.; Jorga, K.; Von Hoff, D.D.; Rudin, C.M.; Reddy, J.C.; Low, J.A.; Lorusso, P.M. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding. Clin. Cancer Res., 2011, 17, 2512-2520.
13. Fournier, T.; Medjoubi, N.; Porquet, D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta, 2000, 1482, 157-171.
14. McNamara, P.J.; Brouwer, K.R.; Gillespie, M.N. Autacoid binding to serum proteins. Interaction of platelet activating factor (PAF) with human serum alpha-1-acid glycoprotein (AAG). Biochem. Pharmacol., 1986, 35, 621-624. (Pubitemid 16049176)
15. McNamara, P.J.; Jewell, R.C.; Gillespie, M.N. The interaction of alpha-1-acid glycoprotein with endogenous autocoids, in particular, platelet activating factor (PAF). Prog. Clin. Biol. Res., 1989, 300, 307-319.
16. Morin, D.; Simon, N.; Depres-Brummer, P.; Levi, F.; Tillement, J.P.; Urien, S. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum. Pharmacology, 1997, 54, 271-275. (Pubitemid 27326258)
17. Ulldemolins, M.; Roberts, J.A.; Rello, J.; Paterson, D.L.; Lipman, J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin. Pharmacokinet., 2011, 50, 99-110.
18. Schonfeld, D.L.; Ravelli, R.B.; Mueller, U.; Skerra, A. The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J. Mol. Biol., 2008, 384, 393-405.
19. Kragh-Hansen, U.; Chuang, V.T.; Otagiri, M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull., 2002, 25, 695-704. (Pubitemid 40036701)
20. Otagiri, M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab. Pharmacokinet., 2005, 20, 309-323.
21. Ceciliani, F.; Pocacqua, V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr. Protein Pept. Sci., 2007, 8, 91-108. (Pubitemid 46322272)
22. Herve, F.; Gomas, E.; Duche, J.C.; Tillement, J.P. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br. J. Clin. Pharmacol., 1993, 36, 241-249. (Pubitemid 23275342)
23. Herve, F.; Duche, J.C.; D'Athis, P.; Marche, C.; Barre, J.; Tillement, J.P. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics, 1996, 6, 403-415. (Pubitemid 26380096)
24. Ishizaki, J.; Fukaishi, A.; Fukuwa, C.; Yamazaki, S.; Tabata, M.; Ishida, T.; Suga, Y.; Arai, K.; Yokogawa, K.; Miyamoto, K. Evaluation of selective competitive binding of basic drugs to alpha1-acid glycoprotein variants. Biol. Pharm. Bull., 2010, 33, 95-99.
25. Belpaire, F.M.; Bogaert, M.G. Pharmacokinetic and pharmacodynamic consequences of altered binding of drugs to alpha 1-acid glycoprotein. Prog. Clin. Biol. Res., 1989, 300, 337-350.
26. Yost, R.L.; DeVane, C.L. Diurnal variation of alpha 1-acid glycoprotein concentration in normal volunteers. J. Pharm. Sci., 1985, 74, 777-779. (Pubitemid 15037869)
27. Jilma, B.; Dirnberger, E.; Loscher, I.; Rumplmayr, A.; Hildebrandt, J.; Eichler, H.G.; Kapiotis, S.; Wagner, O.F. Menstrual cycleassociated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J. Lab. Clin. Med., 1997, 130, 69-75. (Pubitemid 27340790)
28. Parish, R.C.; Spivey, C. Influence of menstrual cycle phase on serum concentrations of alpha 1-acid glycoprotein. Br. J. Clin.Pharmacol., 1991, 31, 197-199.
29. Succari, M.; Foglietti, M.J.; Percheron, F. Microheterogeneity of alpha 1-acid glycoprotein: variation during the menstrual cycle in healthy women, and profile in women receiving estrogenprogestogen treatment. Clin. Chim. Acta, 1990, 187, 235-241.
30. Walle, U.K.; Fagan, T.C.; Topmiller, M.J.; Conradi, E.C.; Walle, T. The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers. Br. J. Clin. Pharmacol., 1994, 37, 21-25. (Pubitemid 24204576)
31. Tsen, L.C.; Arthur, G.R.; Datta, S.; Hornstein, M.D.; Bader, A.M. Estrogen-induced changes in protein binding of bupivacaine during in vitro fertilization. Anesthesiology, 1997, 87, 879-883. (Pubitemid 27456242)
32. Ganz, P.A.; Shell, W.E.; Tokes, Z.A. Evaluation of a radioimmunoassay for alpha 1-acid glycoprotein to monitor therapy of cancer patients. J. Natl. Cancer Inst., 1983, 71, 25-30. (Pubitemid 13030525)
33. Larghero, J.; Leguay, T.; Mourah, S.; Madelaine-Chambrin, I.; Taksin, A.L.; Raffoux, E.; Bastie, J.N.; Degos, L.; Berthaud, P.; Marolleau, J.P.; Calvo, F.; Chomienne, C.; Mahon, F.X.; Rousselot, P. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem. Pharmacol., 2003, 66, 1907-1913. (Pubitemid 37352853)
34. Le Coutre, P.; Kreuzer, K.A.; Na, I.K.; Lupberger, J.; Holdhoff, M.; Appelt, C.; Schwarz, M.; Muller, C.; Gambacorti-Passerini, C.; Platzbecker, U.; Bonnet, R.; Ehninger, G.; Schmidt, C.A. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis., 2002, 28, 75-85. (Pubitemid 34408990)
35. Ishikawa, Y.; Kiyoi, H.; Watanabe, K.; Miyamura, K.; Nakano, Y.; Kitamura, K.; Kohno, A.; Sugiura, I.; Yokozawa, T.; Hanamura, A.; Yamamoto, K.; Iida, H.; Emi, N.; Suzuki, R.; Ohnishi, K.; Naoe, T. Trough plasma concentration of imatinib reflects BCRABL kinase inhibitory activity and clinical response in chronicphase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci., 2010, 101, 2186-2192.
36. Eap, C.B.; Baumann, P. The genetic polymorphism of human alpha 1-acid glycoprotein. Prog. Clin. Biol. Res., 1989, 300, 111-125.
37. Fitos, I.; Visy, J.; Simonyi, M.; Mady, G.; Zsila, F. Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein. Biochim. Biophys. Acta, 2010, 1800, 367-372.
38. Hazai, E.; Visy, J.; Fitos, I.; Bikadi, Z.; Simonyi, M. Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. Bioorg. Med. Chem., 2006, 14, 1959-1965. (Pubitemid 43199527)
39. Nishi, K.; Ono, T.; Nakamura, T.; Fukunaga, N.; Izumi, M.; Watanabe, H.; Suenaga, A.; Maruyama, T.; Yamagata, Y.; Curry, S.; Otagiri, M. Structural insights into differences in drug binding selectivity between two forms of human alfal-acid glycoprotein genetic variants, the A and F1*s forms. J. Biol. Chem., 2011, 286(16), 14427-14434.
40. Nishi, K.; Ueno, M.; Murakami, Y.; Fukunaga, N.; Akuta, T.; Kadowaki, D.; Watanabe, H.; Suenaga, A.; Maruyama, T.; Otagiri, M. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J. Pharm. Sci., 2009, 98, 4316-4326.
41. Jolliet-Riant, P.; Boukef, M.F.; Duche, J.C.; Simon, N.; Tillement, J.P. The genetic variant A of human alpha 1-acid glycoprotein limits the blood to brain transfer of drugs it binds. Life Sci., 1998, 62, L219-L226.
42. Budai, L.; Ozohanics, O.; Ludanyi, K.; Drahos, L.; Kremmer, T.; Krenyacz, J.; Vekey, K. Investigation of genetic variants of alpha-1 acid glycoprotein by ultra-performance liquid chromatographymass spectrometry. Anal. Bioanal. Chem., 2009, 393, 991-998.
43. Eap, C.B.; Fischer, J.F.; Baumann, P. Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. Clin. Chim. Acta, 1991, 203, 379-385.
44. Herve, F.; Duche, J.C.; Jaurand, M.C. Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma. J. Chromatogr. B Biomed. Sci. Appl., 1998, 715, 111-123. (Pubitemid 28403604)
45. Hanada, K.; Yamanaka, E.; Yamamoto, N.; Minami, H.; Kawai, S.; Sasaki, Y.; Ogata, H. Effects of surgery and chronic disease states on the concentrations and phenotype distribution of alpha1-acid glycoprotein: studies in patients with breast cancer and patients with chronic inflammatory disease. Int. J. Clin. Pharmacol. Ther., 2011, 49, 415-421.
46. Imre, T.; Kremmer, T.; Heberger, K.; Molnar-Szollosi, E.; Ludanyi, K.; Pocsfalvi, G.; Malorni, A.; Drahos, L.; Vekey, K. Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. J. Proteomics., 2008, 71, 186-197. (Pubitemid 351927284)
47. Higai, K.; Aoki, Y.; Azuma, Y.; Matsumoto, K. Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation. Biochim. Biophys. Acta, 2005, 1725, 128-135. (Pubitemid 41169183)
48. Imre, T.; Schlosser, G.; Pocsfalvi, G.; Siciliano, R.; Molnar-Szollosi, E.; Kremmer, T.; Malorni, A.; Vekey, K. Glycosylation site analysis of human alpha-1-acid glycoprotein (AGP) by capillary liquid chromatography-electrospray mass spectrometry. J. Mass Spectrom., 2005, 40, 1472-1483. (Pubitemid 41667210)
49. Higai, K.; Azuma, Y.; Aoki, Y.; Matsumoto, K. Altered glycosylation of alpha1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin. Chim. Acta, 2003, 329, 117-125. (Pubitemid 36183490)
50. Shiyan, S.D.; Bovin, N.V. Carbohydrate composition and immunomodulatory activity of different glycoforms of alpha1-acid glycoprotein. Glycoconj. J., 1997, 14, 631-638. (Pubitemid 27353207)
51. Fassbender, K.; Zimmerli, W.; Kissling, R.; Sobieska, M.; Aeschlimann, A.; Kellner, M.; Muller, W. Glycosylation of alpha 1-acid glycoprotein in relation to duration of disease in acute and chronic infection and inflammation. Clin. Chim. Acta, 1991, 203, 315-327.
52. Van Den Heuvel, M.M.; Poland, D.C.; De Graaff, C.S.; Hoefsmit, E.C.; Postmus, P.E.; Beelen, R.H.; Van, D.W. The degree of branching of the glycans of alpha(1)-acid glycoprotein in asthma. A correlation with lung function and inflammatory parameters. Am. J. Respir. Crit Care Med., 2000, 161, 1972-1978. (Pubitemid 30418139)
53. Kuroda, Y.; Kita, Y.; Shibukawa, A.; Nakagawa, T. Role of biantennary glycans and genetic variants of human alpha1-acid glycoprotein in enantioselective binding of basic drugs as studied by high performance frontal analysis/capillary electrophoresis. Pharm. Res., 2001, 18, 389-393. (Pubitemid 32595829)
54. Wong, A.K.; Hsia, J.C. In vitro binding of propranolol and progesterone to native and desialylated human orosomucoid. Can. J. Biochem. Cell Biol., 1983, 61, 1114-1116. (Pubitemid 14249865)
55. Kimura, T.; Shibukawa, A.; Matsuzaki, K. Biantennary glycans as well as genetic variants of alpha1-acid glycoprotein control the enantioselectivity and binding affinity of oxybutynin. Pharm. Res., 2006, 23, 1038-1042. (Pubitemid 43781413)
56. Nishi, K.; Fukunaga, N.; Ono, T.; Akuta, T.; Yumita, N.; Watanabe, H.; Kadowaki, D.; Suenaga, A.; Maruyama, T.; Otagiri, M. Construction of an expression system for human alpha(1)-acid glycoprotein in E. coli: The roles of oligosaccharide moieties in structural and functional properties. Drug Metab. Pharmacokinet., 2010, 25, 200-207.
57. Friedman, M.L.; Wermeling, J.R.; Halsall, H.B. The influence of N-acetylneuraminic acid on the properties of human orosomucoid. Biochem. J., 1986, 236, 149-153. (Pubitemid 16095526)
58. Schmidt, S.; Gonzalez, D.; Derendorf, H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2010, 99, 1107-1122.
59. Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics, Concepts and Applications, 3rd ed.; Lippincott Williams & Wilkins: Philadelphia, 1995.
60. Romach, M.K.; Piafsky, K.M.; Abel, J.G.; Khouw, V.; Sellers, E.M. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin. Pharmacol. Ther., 1981, 29, 211-217. (Pubitemid 11139898)
61. Van Steeg, T.J.; Krekels, E.H.; Danhof, M.; De Lange, E.C. Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats. J. Pharmacol. Toxicol. Methods, 2007, 56, 72-78. (Pubitemid 46829932)
62. Dello, C.P.; Belpaire, F.M.; De, R.A.; Fraeyman, N.H. Influence of inflammation on serum concentration, molecular heterogeneity and drug binding properties of canine alpha-1-acid glycoprotein. J. Vet. Pharmacol. Ther., 1988, 11, 71-76.
63. Gambacorti-Passerini, C.; Zucchetti, M.; Russo, D.; Frapolli, R.; Verga, M.; Bungaro, S.; Tornaghi, L.; Rossi, F.; Pioltelli, P.; Pogliani, E.; Alberti, D.; Corneo, G.; D'Incalci, M. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin. Cancer Res., 2003, 9, 625-632. (Pubitemid 36182594)
64. Goolkasian, D.L.; Slaughter, R.L.; Edwards, D.J.; Lalka, D. Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs. Eur. J. Clin. Pharmacol., 1983, 25, 413-417. (Pubitemid 13005591)
65. Otagiri, M.; Maruyama, T.; Imai, T.; Imamura, Y. Fluorescent investigations of binding of phenprocoumon to alpha 1-acid glycoprotein. J. Pharm. Sci., 1987, 76, 646-649. (Pubitemid 18026349)
66. Pike, E.; Skuterud, B.; Kierulf, P.; Fremstad, D.; Abdel Sayed, S.M.; Lunde, P.K. Binding and displacement of basic, acidic and neutral drugs in normal and orosomucoid-deficient plasma. Clin. Pharmacokinet., 1981, 6, 367-374. (Pubitemid 12165109)
67. Borga, O.; Piafsky, K.M.; Nilsen, O.G. Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate. Clin. Pharmacol. Ther., 1977, 22, 539-544. (Pubitemid 8225568)
68. Kumar, G.N.; Jayanti, V.K.; Johnson, M.K.; Uchic, J.; Thomas, S.; Lee, R.D.; Grabowski, B.A.; Sham, H.L.; Kempf, D.J.; Denissen, J.F.; Marsh, K.C.; Sun, E.; Roberts, S.A. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res., 2004, 21, 1622-1630. (Pubitemid 41184393)
69. Yoo, S.D.; Holladay, J.W.; Fincher, T.K.; Baumann, H.; Dewey, M.J. Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther., 1996, 276, 918-922. (Pubitemid 126660563)
70. von Mehren, M.; Widmer, N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing? Cancer Treat. Rev., 2010, 37, 291-9.
71. Widmer, N.; Decosterd, L.A.; Csajka, C.; Leyvraz, S.; Duchosal, M.A.; Rosselet, A.; Rochat, B.; Eap, C.B.; Henry, H.; Biollaz, J.; Buclin, T. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br. J. Clin. Pharmacol., 2006, 62, 97-112. (Pubitemid 44195246)
72. Widmer, N.; Decosterd, L.A.; Leyvraz, S.; Duchosal, M.A.; Rosselet, A.; Debiec-Rychter, M.; Csajka, C.; Biollaz, J.; Buclin, T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br. J. Cancer, 2008, 98, 1633-1640. (Pubitemid 351684684)
73. Frapolli, R.; Zucchetti, M.; Sessa, C.; Marsoni, S.; Vigano, L.; Locatelli, A.; Rulli, E.; Compagnoni, A.; Bello, E.; Pisano, C.; Carminati, P.; D'Incalci, M. Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to alpha1-acid glycoprotein plasma levels. Eur. J. Cancer, 2010, 46, 505-516.
74. Graham, R.A.; Lum, B.L.; Cheeti, S.; Jin, J.Y.; Jorga, K.; Von Hoff, D.D.; Rudin, C.M.; Reddy, J.C.; Low, J.A.; Lorusso, P.M. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding. Clin. Cancer Res., 2011, 17, 2512-2520.
75. Eap, C.B.; Buclin, T.; Baumann, P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet., 2002, 41, 1153-1193. (Pubitemid 35398691)
76. Abramson, F.P. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. Clin. Pharmacol. Ther., 1982, 32, 652-658. (Pubitemid 13096711)
77. Mouly, S.J.; Paine, M.F.; Watkins, P.B. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal firstpass extraction of saquinavir. J. Pharmacol. Exp. Ther., 2004, 308, 941-948. (Pubitemid 38263969)
78. Barre, J.; Didey, F.; Delion, F.; Tillement, J.P. Problems in therapeutic drug monitoring: free drug level monitoring. Ther. Drug Monit., 1988, 10, 133-143. (Pubitemid 18098680)
79. Trainor, G.L. The importance of plasma protein binding in drug discovery. Exp. Opin. Drug Discov., 2007, 2, 51-64. (Pubitemid 47078697)
80. Fischl, M.A.; Richman, D.D.; Flexner, C.; Para, M.F.; Haubrich, R.; Karim, A.; Yeramian, P.; Holden-Wiltse, J.; Meehan, P.M. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 1997, 15, 28-34.
81. Bilello, J.A.; Bilello, P.A.; Prichard, M.; Robins, T.; Drusano, G.L. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J. Infect. Dis., 1995, 171, 546-551.
82. Bilello, J.A.; Bilello, P.A.; Kort, J.J.; Dudley, M.N.; Leonard, J.; Drusano, G.L. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob. Agents Chemother., 1995, 39, 2523-2527.
83. Kageyama, S.; Anderson, B.D.; Hoesterey, B.L.; Hayashi, H.; Kiso, Y.; Flora, K.P.; Mitsuya, H. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother., 1994, 38, 1107-1111. (Pubitemid 24150846)
84. Benet, L.Z.; Hoener, B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther., 2002, 71, 115-121. (Pubitemid 34271114)
85. Smith, D.A.; Di, L.; Kerns, E.H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. Drug Discov., 2010, 9, 929-939.
86. Ozawa, K.; Minami, H.; Sato, H. [Proposal of a novel dosing schedule of docetaxel by using alpha1-acid glycoprotein as an index]. Yakugaku Zasshi, 2009, 129, 1565-1572.
87. Loos, W.J.; Baker, S.D.; Verweij, J.; Boonstra, J.G.; Sparreboom, A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin. Pharmacol. Ther., 2003, 74, 364-371. (Pubitemid 37222857)
88. Bruno, R.; Olivares, R.; Berille, J.; Chaikin, P.; Vivier, N.; Hammershaimb, L.; Rhodes, G.R.; Rigas, J.R. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res., 2003, 9, 1077-1082. (Pubitemid 36323714)
89. Bruno, R.; Vivier, N.; Vergniol, J.C.; De Phillips, S.L.; Montay, G.; Sheiner, L.B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm., 1996, 24, 153-172. (Pubitemid 26300483)
90. Aguirre, C.; Troconiz, I.F.; Valdivieso, A.; Jimenez, R.M.; Gonzalez, J.P.; Calvo, R.; Rodriguez-Sasiain, J.M. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Res. Commun. Mol. Pathol. Pharmacol., 1996, 92, 53-72. (Pubitemid 26149853)
91. Levinson, I.; Levine, S. Negative correlation between alpha-1-acidglycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia. Biol. Psychiatry, 1995, 38, 198-200.
92. Dente, L.; Ruther, U.; Tripodi, M.; Wagner, E.F.; Cortese, R. Expression of human alpha 1-acid glycoprotein genes in cultured cells and in transgenic mice. Genes Dev., 1988, 2, 259-266.
93. Holladay, J.W.; Dewey, M.J.; Yoo, S.D. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels. Drug Metab. Dispos., 1998, 26, 20-24. (Pubitemid 28071319)
94. Jauregizar, N.; Calvo, R.; Suarez, E.; Quintana, A.; Raczka, E.; Lukas, J.C. Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels. Pharm. Res., 2001, 18, 838-845. (Pubitemid 32783521)
95. Martinez, J.R.; Aguirre, C.; Calvo, R.; Rodriguez-Sasiain, J.M.; Erill, S. Decrease in penbutolol central response as a cause of changes in its serum protein binding. J. Pharm. Pharmacol., 1990, 42, 164-166. (Pubitemid 20266216)
96. Yang, J.; Jamei, M.; Yeo, K.R.; Rostami-Hodjegan, A.; Tucker, G.T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos., 2007, 35, 501-502. (Pubitemid 46333921)
97. Rowland, M.; Benet, L.Z.; Graham, G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm., 1973, 1, 123-136.
98. Wilkinson, G.R.; Shand, D.G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther., 1975, 18, 377-390.
99. Zsila, F. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications. Curr. Drug Metab., 2007, 8, 563-593. (Pubitemid 47209096)
100. Eap, C.B.; Cuendet, C.; Baumann, P. Binding of d-methadone, lmethadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin. Pharmacol. Ther., 1990, 47, 338-346. (Pubitemid 20115020)
101. Jolliet, P.; Simon, N.; Bree, F.; Urien, S.; Pagliara, A.; Carrupt, P.A.; Testa, B.; Tillement, J.P. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm. Res., 1997, 14, 650-656. (Pubitemid 27220285)
102. Rodriguez, M.; Ortega, I.; Soengas, I.; Leal, N.; Suarez, E.; Calvo, R.; Lukas, J.C. Alpha-1-acid glycoprotein directly affects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding. J. Pharm. Sci., 2004, 93, 2836-2850. (Pubitemid 39506633)
103. Slaviero, K.A.; Clarke, S.J.; Rivory, L.P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol., 2003, 4, 224-232. (Pubitemid 36503320)
104. Rivory, L.P.; Slaviero, K.A.; Clarke, S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer, 2002, 87, 277-280.
105. Van Steeg, T.J.; Freijer, J.; Danhof, M.; De Lange, E.C. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. Br. J. Pharmacol., 2007, 151, 356-366. (Pubitemid 46842675)
106. Van Steeg, T.J.; Freijer, J.; Danhof, M.; De Lange, E.C. Mechanismbased pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonistantagonist interaction model. J. Pharmacol. Exp. Ther., 2008, 324, 1234-1242. (Pubitemid 351397831)
107. Van Steeg, T.J.; Boralli, V.B.; Krekels, E.H.; Slijkerman, P.; Freijer, J.; Danhof, M.; De Lange, E.C. Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach. J. Pharm. Sci., 2009, 98, 3816-3828.
108. Van Steeg, T.J.; Krekels, E.H.; Freijer, J.; Danhof, M.; De Lange, E.C. Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). J. Pharm. Sci., 2010, 99, 2511-2520.
109. Akinaga, S.; Sugiyama, K.; Akiyama, T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anticancer Drug Des., 2000, 15, 43-52. (Pubitemid 30364898)
110. Fuse, E.; Tanii, H.; Kurata, N.; Kobayashi, H.; Shimada, Y.; Tamura, T.; Sasaki, Y.; Tanigawara, Y.; Lush, R.D.; Headlee, D.; Figg, W.D.; Arbuck, S.G.; Senderowicz, A.M.; Sausville, E.A.; Akinaga, S.; Kuwabara, T.; Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res., 1998, 58, 3248-3253. (Pubitemid 28371060)
111. Giannetti, A.M.; Wong, H.; Dijkgraaf, G.J.; Dueber, E.C.; Ortwine, D.F.; Bravo, B.J.; Gould, S.E.; Plise, E.G.; Lum, B.L.; Malhi, V.; Graham, R.A. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J. Med. Chem., 2011, 54, 2592-2601.
112. Kurata, N.; Kuwabara, T.; Tanii, H.; Fuse, E.; Akiyama, T.; Akinaga, S.; Kobayashi, H.; Yamaguchi, K.; Kobayashi, S. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemother. Pharmacol., 1999, 44, 12-18. (Pubitemid 29246320)
113. Sausville, E.A.; Lush, R.D.; Headlee, D.; Smith, A.C.; Figg, W.D.; Arbuck, S.G.; Senderowicz, A.M.; Fuse, E.; Tanii, H.; Kuwabara, T.; Kobayashi, S. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother. Pharmacol., 1998, 42 Suppl, S54-S59.
114. Abe, S.; Kubota, T.; Otani, Y.; Furukawa, T.; Watanabe, M.; Kumai, K.; Akiyama, T.; Akinaga, S.; Kitajima, M. UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. Jpn. J. Cancer Res., 2001, 92, 537-545. (Pubitemid 32515095)
115. Akinaga, S.; Gomi, K.; Morimoto, M.; Tamaoki, T.; Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 1991, 51, 4888-4892.
116. Fuse, E.; Kuwabara, T.; Sparreboom, A.; Sausville, E.A.; Figg, W.D. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J. Clin. Pharmacol., 2005, 45, 394-403. (Pubitemid 40490412)
117. Diarra-Mehrpour, M.; Bourguignon, J.; Leroux-Nicollet, I.; Marko-Vercaigne, D.; Biou, D.; Hiron, M.; Lebreton, J.P. The effects of 17 alpha-ethynyloestradiol and of acute inflammation on the plasma concentration of rat alpha 1-acid glycoprotein and on the induction of its hepatic mRNA. Biochem. J., 1985, 225, 681-687. (Pubitemid 15174258)
118. Arnold, F.J.; Meyerson, L.R. Radial immunodiffusion assay for rat alpha 1-acid glycoprotein. Pharmacol. Biochem. Behav., 1990, 37, 485-491.
119. Terao, N.; Shen, D.D. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J. Pharmacol. Exp. Ther., 1983, 227, 369-375. (Pubitemid 14241128)
120. Yasuhara, M.; Fujiwara, J.; Kitade, S.; Katayama, H.; Okumura, K.; Hori, R. Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther., 1985, 235, 513-520. (Pubitemid 16248753)
121. Arnold, F.J.; Meyerson, L.R. Olfactory bulbectomy alters alpha-1 acid glycoprotein levels in rat plasma. Brain Res. Bull., 1990, 25, 259-262. (Pubitemid 20277314)
122. Raynes, J.G. Serum concentrations of lipid bound sialic acid and acute phase proteins in patients with cancer and nonmalignant disease. Biomed. Pharmacother., 1983, 37, 136-138. (Pubitemid 13018079)
123. Bloedow, D.C.; Hansbrough, J.F.; Hardin, T.; Simons, M. Postburn serum drug binding and serum protein concentrations. J. Clin. Pharmacol., 1986, 26, 147-151. (Pubitemid 16134438)
124. Chu, J.S.; Kishion, S.; Nomura, A.; Miyazaki, K. Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. Zhongguo Yao Li Xue. Bao., 1997, 18, 408-410. (Pubitemid 27389442)
125. Freilich, D.I.; Giardina, E.G. Imipramine binding to alpha-1-acid glycoprotein in normal subjects and cardiac patients. Clin. Pharmacol. Ther., 1984, 35, 670-674. (Pubitemid 14108754)
126. Herve, F.; Caron, G.; Duche, J.C.; Gaillard, P.; Abd, R.N.; Tsantili-Kakoulidou, A.; Carrupt, P.A.; D'Athis, P.; Tillement, J.P.; Testa, B. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol. Pharmacol., 1998, 54, 129-138. (Pubitemid 28337595)
127. Hanada, K.; Tochikura, N.; Ogata, H. Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. Biol. Pharm. Bull., 2007, 30, 1593-1595. (Pubitemid 47282218)
128. Garrido, M.J.; Jiminez, R.; Gomez, E.; Calvo, R. Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal. J. Pharm. Pharmacol., 1996, 48, 281-284. (Pubitemid 26159144)
129. Garrido, M.J.; Valle, M.; Calvo, R.; Troconiz, I.F. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J. Pharmacol. Exp. Ther., 1999, 288, 179-187. (Pubitemid 29113489)
130. Komori, T.; Shimoishi, K.; Harashima, H.; Otagiri, M. Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. Biol. Pharm. Bull., 1998, 21, 1376-1378. (Pubitemid 29021806)
131. Belpaire, F.M.; Bogaert, M.G.; Mugabo, P.; Rosseel, M.T. Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats
132. Belpaire, F.M.; de, S.F.; Chindavijak, B.; Fraeyman, N.; Bogaert, M.G. Effect of turpentine-induced inflammation on the disposition kinetics of propranolol, metoprolol, and antipyrine in the rat. Fundam. Clin. Pharmacol., 1989, 3, 79-88. (Pubitemid 19102619)
133. Sugihara, N.; Furuno, K.; Kita, N.; Murakami, T.; Yata, N. The influence of increased plasma protein binding on the disposition of quinidine in turpentine-treated rats. Biol. Pharm. Bull., 1993, 16, 63-67. (Pubitemid 23121751)
134. Holladay, J.W.; Dewey, M.J.; Michniak, B.B.; Wiltshire, H.; Halberg, D.L.; Weigl, P.; Liang, Z.; Halifax, K.; Lindup, W.E.; Back, D.J. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab. Dispos., 2001, 29, 299-303. (Pubitemid 32179531)
135. Matsushima, H.; Watanabe, T.; Higuchi, S. Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. J. Pharm. Sci., 2000, 89, 490-498.
136. Hedaya, M.A.; Daoud, S.S. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. Anticancer Res., 2001, 21, 4005-4010. (Pubitemid 34229277)
137. Evans, S.M.; Robertson, I.G.; Paxton, J.W. Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. J. Pharm. Pharmacol., 1994, 46, 63-67. (Pubitemid 24047059)
138. Prueksaritanont, T.; Fernandez-Metzler, C.; Meng, Y.; Barrish, A.; Halczenko, W.; Rodan, S.B.; Hutchinson, J.H.; Duggan, M.E.; Lin, J.H. Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to man. Xenobiotica, 2004, 34, 103-115. (Pubitemid 38187066)
139. Kiriyama, A.; Nishiura, T.; Ishino, M.; Yamamoto, Y.; Ogita, I.; Kiso, Y.; Takada, K. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor. Biopharm. Drug Dispos., 1996, 17, 739-751. (Pubitemid 26409350)
140. Matsubara, Y.; Kanazawa, T.; Kojima, Y.; Abe, Y.; Kobayashi, K.; Kanbe, H.; Harada, H.; Momose, Y.; Terakado, S.; Adachi, Y.; Midgley, I. [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi, 2006, 126 Spec no., 237-245.
141. Acharya, M.R.; Sparreboom, A.; Sausville, E.A.; Conley, B.A.; Doroshow, J.H.; Venitz, J.; Figg, W.D. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother. Pharmacol., 2006, 57, 275-281. (Pubitemid 41827349)
142. Bertucci, C.; Domenici, E. Reversible and Covalent Binding of Drugs to Human Serum Albumin: Methodological Approaches and Physiological Relevance. Curr. Med. Chem., 2002, 9, 1463-1481. (Pubitemid 34823027)
143. Wasan, K.M.; Brocks, D.R.; Lee, S.D.; Sachs-Barrable, K.; Thornton, S.J. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat. Rev. Drug Discov., 2008, 7(1),84-99.
144. Hinderling, P.H. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol. Rev. 1997, 49(3), 279-295. (Pubitemid 27414916)